CPHI Barcelona 2023: SINOVAC Showcases Comprehensive Product Portfolio

2023-10-19

Pioneering Antibody Products and WHO Approved Vaccines Will Advance Prevention and Treatment of Infectious Diseases

October 19, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, will showcase groundbreaking products and an extensive portfolio targeting various infectious diseases at CPHI Barcelona 2023, Booth 1D41 (Zone FDF), from October 24 to 26.

Notably, SINOVAC will debut the Antibody SA55 Injection and Nasal Spray, based on an innovative broad-spectrum neutralizing antibody that advances the treatment and prevention of COVID-19. Recent studies shows these products’ efficacy in neutralizing the omicron variant and its sublineages, including BA.5, BF.7, BQ.1.1, XBB.1.5, BA.2.86 and EG.5.

In addition to these innovative antibody products, SINOVAC will showcase:

· World Health Organization (WHO) prequalified vaccines, including Healive^® for hepatitis A; PROVARIX for varicella; and a vaccine for Sabin-strain inactivated polio.

· Highly protective trivalent influenza vaccine, Anflu^®, and quadrivalent influenza vaccine, TetrAnflu.

· World-leading enterovirus type 71 vaccine, Inlive^®.

· CoronaVac^®, one of the most widely administered COVID-19 vaccines globally and the only inactivated COVID-19 vaccine approved for children as young as 6 months old.

"While the WHO has declared an end to the global health emergency caused by COVID-19, the world is still facing the threat of various infectious diseases in 2023," said Ms. Helen Yang, Chief Business Officer of SINOVAC. "As a leading biopharmaceutical product provider in China, SINOVAC remains committed to increasing our investment in R&D, vaccine production and the exploration of cutting-edge biomedical products, including antibodies. It is the right time to introduce our most recent innovations and explore opportunities for international collaboration that aids in our mission to 'Supply Vaccines to Eliminate Human Diseases'."

Discover SINOVAC's comprehensive product portfolio at CPHI Barcelona 2023

Explore SINOVAC's comprehensive portfolio of products and technologies and meet with SINOVAC experts onsite at Booth 1D41 (Zone FDF) or contact Alice Chen via info@sinovac.com to schedule a personalized engagement.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Paneflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.

Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

For more information, please see the Company’s website at www.sinovac.com.